In this context the study done by Chung et al., demonstrated that plasma derived extracellular vesicle (EVs)-borne tau and β-amyloid have the potential to be used as a biomarker for Parkinson’s disease (PD). This evidence concerns the gene MAPT and Parkinson disease.